Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Sexually Transmitted Diseases 1Papillomavirus Infections 1Lung Neoplasms 1Condylomata Acuminata 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × ranpirnase × Clear all
NCT02535104 2018-06-06

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Tamir Biotechnology, Inc.

Phase 1/2 Completed
70 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Papillomavirus Infections

NCT01184287 2015-09-02

A Study Of Ranpirnase(OnconaseĀ®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer

Tamir Biotechnology, Inc.

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔